文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肯尼亚和乌干达艾滋病毒血清学不一致伴侣暴露前预防示范项目中依从性与艾滋病毒感染风险的比对:预防有效依从性的前瞻性分析

Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.

作者信息

Haberer Jessica E, Kidoguchi Lara, Heffron Renee, Mugo Nelly, Bukusi Elizabeth, Katabira Elly, Asiimwe Stephen, Thomas Katherine K, Celum Connie, Baeten Jared M

机构信息

Massachusetts General Hospital Global Health, Boston, MA, USA.

Department of Medicine, Harvard Medical School, Boston, MA, USA.

出版信息

J Int AIDS Soc. 2017 Jul 25;20(1):21842. doi: 10.7448/IAS.20.1.21842.


DOI:10.7448/IAS.20.1.21842
PMID:28741331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5577705/
Abstract

INTRODUCTION: Adherence is essential for pre-exposure prophylaxis (PrEP) to protect against HIV acquisition, but PrEP use need not be life-long. PrEP is most efficient when its use is aligned with periods of risk - a concept termed prevention-effective adherence. The objective of this paper is to describe prevention-effective adherence and predictors of adherence within an open-label delivery project of integrated PrEP and antiretroviral therapy (ART) among HIV serodiscordant couples in Kenya and Uganda (the Partners Demonstration Project). METHODS: We offered PrEP to HIV-uninfected participants until the partner living with HIV had taken ART for ≥6 months (a strategy known as "PrEP as a bridge to ART"). The level of adherence sufficient to protect against HIV was estimated in two ways: ≥4 and ≥6 doses/week (per electronic monitoring). Risk for HIV acquisition was considered if the couple reported sex with <100% condom use before six months of ART, if they reported sex but had 100% condom use and/or six months of ART and if no sex was reported. We assessed prevention-effective adherence by cross-tabulating PrEP use with HIV risk and used multivariable regression models to assess predictors of ≥4 and ≥6 doses/week. A total of 985 HIV-uninfected participants initiated PrEP; 67% were male, median age was twenty-nine years, and 67% reported condomless sex in the month before enrolment. An average of ≥4 doses and ≥6 doses/week were taken in 81% and 67% of participant-visits, respectively. Adherence sufficient to protect against HIV acquisition was achieved in 75-88% of participant-visits with high HIV risk. The strongest predictor of achieving sufficient adherence was reporting sex with the study partner who was living with HIV; other statistically significant predictors included no concerns about daily PrEP, pregnancy or pregnancy intention, females aged >25 years, older male partners and desire for relationship success. Predictors of not achieving sufficient adherence were no longer being a couple, delayed PrEP initiation, >6 months  of follow-up, ART use >6 months  by the partner living with HIV and problem alcohol use. CONCLUSIONS: Over three-quarters of participant-visits by HIV-uninfected partners in serodiscordant couples achieved prevention-effective adherence with PrEP. Greater adherence was observed during months with HIV risk and the strongest predictor of achieving sufficient adherence was sexual activity.

摘要

引言:坚持服用暴露前预防药物(PrEP)对于预防感染艾滋病毒至关重要,但PrEP的使用并非需要终身进行。当PrEP的使用与风险期相匹配时最为有效——这一概念被称为预防有效依从性。本文的目的是描述在肯尼亚和乌干达的艾滋病毒血清学不一致夫妻中开展的PrEP与抗逆转录病毒疗法(ART)综合开放标签交付项目(伙伴示范项目)中的预防有效依从性及依从性预测因素。 方法:我们为未感染艾滋病毒的参与者提供PrEP,直至其感染艾滋病毒的伴侣接受抗逆转录病毒治疗≥6个月(一种被称为“PrEP作为通向抗逆转录病毒治疗的桥梁”的策略)。通过两种方式估计足以预防艾滋病毒感染的依从性水平:≥4剂/周和≥6剂/周(通过电子监测)。如果夫妻报告在抗逆转录病毒治疗6个月之前性行为时未100%使用安全套,或者报告有性行为但100%使用安全套和/或已接受抗逆转录病毒治疗6个月,以及如果报告无性行为,则被视为有感染艾滋病毒的风险。我们通过将PrEP使用情况与艾滋病毒风险进行交叉制表来评估预防有效依从性,并使用多变量回归模型来评估≥4剂/周和≥6剂/周的预测因素。共有985名未感染艾滋病毒的参与者开始服用PrEP;67%为男性,中位年龄为29岁,67%的参与者在入组前一个月报告有无保护性行为。分别有81%和67%的参与者访视中平均每周服用≥4剂和≥6剂。在75 - 88%的高艾滋病毒风险参与者访视中实现了足以预防艾滋病毒感染的依从性。实现足够依从性的最强预测因素是报告与感染艾滋病毒的研究伴侣有性行为;其他具有统计学意义的预测因素包括对每日服用PrEP、怀孕或怀孕意愿无担忧、年龄>25岁的女性、年龄较大的男性伴侣以及渴望关系成功。未实现足够依从性的预测因素包括不再是夫妻、PrEP启动延迟、随访>6个月、感染艾滋病毒的伴侣使用抗逆转录病毒治疗>6个月以及有问题的饮酒行为。 结论:在血清学不一致夫妻中,未感染艾滋病毒的伴侣超过四分之三的参与者访视实现了PrEP的预防有效依从性。在有艾滋病毒风险的月份中观察到更高的依从性,而实现足够依从性的最强预测因素是性活动。

相似文献

[1]
Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence.

J Int AIDS Soc. 2017-7-25

[2]
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.

PLoS Med. 2016-8-23

[3]
Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention.

J Acquir Immune Defic Syndr. 2017-1-1

[4]
Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the "PrEP as a bridge to ART" strategy.

BMC Public Health. 2020-10-28

[5]
Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa.

J Acquir Immune Defic Syndr. 2017-12-15

[6]
Implementation of a comprehensive safer conception intervention for HIV-serodiscordant couples in Kenya: uptake, use and effectiveness.

J Int AIDS Soc. 2019-4

[7]
Sexual Behaviors After PrEP Discontinuation Among HIV Serodiscordant Couples in Kenya and Uganda.

J Acquir Immune Defic Syndr. 2020-10-1

[8]
Beyond HIV prevention: everyday life priorities and demand for PrEP among Ugandan HIV serodiscordant couples.

J Int AIDS Soc. 2019-1

[9]
Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.

J Int AIDS Soc. 2015-7-20

[10]
Brief Report: PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships.

J Acquir Immune Defic Syndr. 2018-1-1

引用本文的文献

[1]
Real-time digital intervention on oral pre-exposure prophylaxis adherence among MSM: randomized controlled trial.

NPJ Digit Med. 2025-6-11

[2]
Motivations for Starting and Stopping PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial.

AIDS Behav. 2025-6-3

[3]
HIV pre-exposure prophylaxis use during periods of unprotected sex among female sex workers in Tanga city, Tanzania: a control arm analysis of the pragmatic quasi-experimental trial.

Front Public Health. 2024

[4]
Preference for novel biomedical HIV pre-exposure prophylaxis methods among adolescent girls and young women in Kampala, Uganda: a mixed methods study.

Front Public Health. 2024

[5]
Discordance Between HIV Risk Perception, Sexual Behavior, and Pre-exposure Prophylaxis Adherence Among Young Sexual and Gender Minorities in the United States.

J Adolesc Health. 2024-6

[6]
Evaluating the use of oral pre-exposure prophylaxis among pregnant and postpartum adolescent girls and young women in Cape Town, South Africa.

Front Reprod Health. 2023-9-19

[7]
Dynamicity of HIV Pre-exposure Prophylaxis Usage Pattern and Association with Executed Adherence in MSM: An Implementation Study in Hong Kong.

AIDS Behav. 2024-4

[8]
Dynamics of Pre-Exposure (PrEP) Eligibility Because of Waxing and Waning of HIV Risk in Rakai, Uganda.

J Acquir Immune Defic Syndr. 2023-6-1

[9]
Integration of COVID-19 and TB screening in Kampala, Uganda: healthcare provider perspectives.

Implement Sci Commun. 2023-1-17

[10]
Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.

J Int AIDS Soc. 2022-12

本文引用的文献

[1]
Raising Awareness of Pre-Exposure Prophylaxis (PrEP) among Women in New York City: Community and Provider Perspectives.

J Health Commun. 2017-3

[2]
A Multi-US City Assessment of Awareness and Uptake of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Black Men and Transgender Women Who Have Sex with Men.

Prev Sci. 2017-7

[3]
Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention.

J Acquir Immune Defic Syndr. 2017-1-1

[4]
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.

J Acquir Immune Defic Syndr. 2017-1-1

[5]
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.

PLoS Med. 2016-8-23

[6]
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.

J Acquir Immune Defic Syndr. 2017-1-1

[7]
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

J Infect Dis. 2016-7-1

[8]
Short message service (SMS) reminders and real-time adherence monitoring improve antiretroviral therapy adherence in rural Uganda.

AIDS. 2016-5-15

[9]
Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.

Curr Opin HIV AIDS. 2016-1

[10]
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

N Engl J Med. 2015-12-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索